Verteporfin: restriction of indications: labelling change. A welcome move. A negative risk-benefit balance in neovascular forms of ARMD with "occult" lesions.
D017277:Drug Approval; D004348:Drug Labeling; D005060:Europe; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D010778:Photochemotherapy; D011166:Porphyrins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D011166:Porphyrins